{"product_id":"evlo-vrio-analysis","title":"Evelo Biosciences, Inc. (EVLO): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eUnlock the strategic DNA of Evelo Biosciences, Inc. (EVLO) as we dissect its core competencies through the rigorous VRIO framework, testing its resources for true Value, Rarity, Inimitability, and Organization. This distilled summary cuts straight to the heart of its competitive standing, revealing precisely where its sustainable advantages lie - or where critical gaps threaten its market leadership. Engage with the analysis below to grasp the immediate implications of these findings.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvelo Biosciences, Inc. (EVLO) - VRIO Analysis: Platform Technology: SINTAX (Small Intestinal Axis)\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at a platform technology that, frankly, had the right idea but couldn't stick the landing. The SINTAX platform - that’s the Small Intestinal Axis - was designed to use oral microbes to dial down systemic immunity, a genuinely compelling concept for chronic inflammation. The problem, as the numbers show, is that the promise never translated into a successful product before the lights went out.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eThe core value proposition was modulating systemic immunity through an oral delivery system, which avoids injections - a big plus for patient compliance. The idea was to treat conditions like psoriasis and atopic dermatitis without the usual hurdles. For instance, the initial Phase 2 trial for EDP1815 in psoriasis showed some encouraging durability, with 18 out of 30 patients maintaining a PASI-50 response or greater at 24 weeks post-treatment, even after stopping the drug. That durability suggested real biological activity.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eWhen conceived, targeting the gut-body network with this specific mechanism was quite rare in the biotech space. It wasn't just another small molecule; it was a novel approach to immune regulation. However, rarity alone doesn't save a company if the execution falters. The novelty was high, but the market quickly discounted it when the clinical data didn't support the mechanism consistently.\u003c\/p\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eHonestly, the underlying biological concept - harnessing the gut for systemic immune control - is inherently difficult to copy quickly because it requires deep, proprietary biological understanding. Still, the execution risk proved massive. Look at the Phase 2 atopic dermatitis trial for EDP1815: the first three cohorts saw EASI-50 responses of 41%, 38%, and 32%, but the placebo response was 56%. That kind of noise makes the platform's specific output hard to prove as truly unique when compared to the placebo effect in that trial setting.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eThis is where the story ends. The organization simply failed to translate the platform into approved products, leading to its dissolution in November 2023. The company stopped development on EDP2939 after its Phase 2 psoriasis trial missed the primary endpoint. By the time they announced the shutdown, they were burning cash, with operating cash flow at -$73.70 million in the last 12 months, and total liabilities of $39.76 million against only $17.3 million in cash as of September 30, 2023. The organization wasn't structured, funded, or agile enough to navigate the clinical setbacks.\u003c\/p\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eThe competitive advantage was, at best, Temporary. The platform’s potential was never realized. You can see the final state reflected in the 2025 fiscal data: revenue for the last four quarters ending September 30, 2025, was $0, and the market cap was listed as 3,797. A temporary advantage that expires when the company ceases operations is no advantage at all.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the VRIO assessment:\u003c\/p\u003e\n\u003ctable border=\"1\"\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n    \u003ctd\u003eAssessment\u003c\/td\u003e\n    \u003ctd\u003eKey Supporting Data Point\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eValue\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eDemonstrated durable response in EDP1815 psoriasis follow-up (\u003cstrong\u003e18\/30\u003c\/strong\u003e patients at PASI-50 at Week 24)\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eRarity\u003c\/td\u003e\n    \u003ctd\u003eYes\u003c\/td\u003e\n    \u003ctd\u003eNovel oral mechanism targeting the gut-body axis\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eInimitability\u003c\/td\u003e\n    \u003ctd\u003eNo\u003c\/td\u003e\n    \u003ctd\u003eClinical failures (e.g., EDP2939 missing primary endpoint) devalued execution\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eOrganization\u003c\/td\u003e\n    \u003ctd\u003eNo\u003c\/td\u003e\n    \u003ctd\u003eCompany dissolved in November 2023 due to lack of funding and trial failures\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n    \u003ctd\u003eTemporary\u003c\/td\u003e\n    \u003ctd\u003eZero revenue in the last four reported quarters of FY2025\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eWhat this estimate hides is the high upfront R\u0026amp;D cost sunk into the platform before the failures. The path forward for any acquirer would be a massive undertaking in de-risking the core biology, not just adopting a ready-to-launch asset. The key takeaways from the platform's history are:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEDP1815 Atopic Dermatitis Cohort 4 EASI-50 response: 37.9% vs. placebo 44.7%.\u003c\/li\u003e\n\u003cli\u003eEDP2939 Psoriasis trial showed inferiority to placebo at Week 16 (19.6% vs. 25%).\u003c\/li\u003e\n\u003cli\u003eTotal Liabilities exceeded cash by over $22 million as of late 2023.\u003c\/li\u003e\n\u003cli\u003eThe stock traded near $0.0005000 in 2025 forecasts, down from a $16 IPO price in 2018.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft final asset disposition report by end of month.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvelo Biosciences, Inc. (EVLO) - VRIO Analysis: Intellectual Property Estate (Patents)\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eProvides exclusive rights to specific microbial strains and their use in treating cancer and inflammation. Estimated total value of intellectual property estate: \u003cstrong\u003e$42.5 million\u003c\/strong\u003e as of December 31, 2022.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Funding Raised\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$167M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLast Financing Proceeds (July 2023)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$25.5 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt as of June 2023\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.9 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003ePatents exist, but their value is tied to the commercial viability of the underlying science. Portfolio as of December 31, 2022: \u003cstrong\u003e37\u003c\/strong\u003e issued patents and \u003cstrong\u003e26\u003c\/strong\u003e pending patent applications.\u003c\/p\u003e\n\u003cp\u003e\n\u003c\/p\u003e\u003cul\u003e\n\u003cli\u003eIssued U.S. Patents (as of March 5, 2021): \u003cstrong\u003e12\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003ePending Patent Applications (as of December 31, 2022): \u003cstrong\u003e26\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Patent Families (as of March 5, 2021): \u003cstrong\u003e51\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003ePatents are legally protected, but their market value is low if the technology fails trials. Seven of the U.S. patents were exclusively licensed from the Mayo Clinic Foundation for Medical Education and Research as of March 5, 2021.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe IP was not successfully leveraged to secure ongoing financing or partnerships. Company status: \u003cstrong\u003eDissolution\u003c\/strong\u003e initiated November 2023.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eTemporary; IP value is contingent on a buyer finding utility in the assets during liquidation. IPO share price in 2018 was \u003cstrong\u003e$16\u003c\/strong\u003e per share; shares lost almost all value by November 2023.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvelo Biosciences, Inc. (EVLO) - VRIO Analysis: Lead Candidate Asset: EDP1815 (Historical)\n\u003c\/h2\u003e\n\u003cp\u003eHistorical value as a potential oral therapy for psoriasis and atopic dermatitis, now zero as development stopped.\u003c\/p\u003e\n\u003cp\u003eThe asset demonstrated preliminary efficacy in mild to moderate psoriasis Phase 2 trials:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePASI-50 response at week 16: 25% to 32% across three EDP1815 cohorts versus 12% on placebo.\u003c\/li\u003e\n\u003cli\u003ePooled PASI-50 response across all three cohorts: 29% versus 12% for placebo, with a p-value of 0.027.\u003c\/li\u003e\n\u003cli\u003eBayesian analysis provided probabilities that EDP1815 was superior to placebo ranging from 80% to 90% for the 16-week primary endpoint.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eDevelopment in atopic dermatitis was ceased following a Phase 2 trial where EASI-50 or greater responses were achieved in 41%, 38%, and 32% of patients in cohorts 1, 2, and 3, respectively, while the overall placebo EASI-50 response was 56%.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eTrial Phase\u003c\/th\u003e\n\u003cth\u003eEDP1815 Response Rate (Primary Endpoint)\u003c\/th\u003e\n\u003cth\u003ePlacebo Response Rate\u003c\/th\u003e\n\u003cth\u003eStatistical Significance\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePsoriasis\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003ctd\u003ePASI-50 response: 25% to 32% (Pooled: 29%)\u003c\/td\u003e\n\u003ctd\u003e12%\u003c\/td\u003e\n\u003ctd\u003eStatistically significant (p \u0026lt;0.05 for cohorts 1 \u0026amp; 2; pooled p=\u003cstrong\u003e0.027\u003c\/strong\u003e)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAtopic Dermatitis\u003c\/td\u003e\n\u003ctd\u003ePhase 2\u003c\/td\u003e\n\u003ctd\u003eEASI-50 response: 41%, 38%, 32% (Cohorts 1-3)\u003c\/td\u003e\n\u003ctd\u003e56% (Overall)\u003c\/td\u003e\n\u003ctd\u003eNot met (Outperformed by placebo)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eLow; many companies pursue similar inflammatory targets, though the delivery method was unique.\u003c\/p\u003e\n\u003cp\u003eHigh; competitors can develop similar oral biologics if the mechanism is proven.\u003c\/p\u003e\n\u003cp\u003eNot Applicable; the asset was terminated due to poor Phase 2 results in atopic dermatitis, and subsequent focus shifted to EDP2939 for psoriasis.\u003c\/p\u003e\n\u003cp\u003eNone; development was halted following trial failures in atopic dermatitis and subsequent focus shift away from EDP1815 in psoriasis.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvelo Biosciences, Inc. (EVLO) - VRIO Analysis: Pipeline Candidate: EDP2939 (Historical)\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003ePipeline Candidate: EDP2939 (Historical)\u003c\/strong\u003e\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Historical potential for psoriasis treatment, now zero as development was stopped after missing trial goals. The Phase 2 study's primary endpoint was not achieved on October 17, 2023.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Low; another asset in the same therapeutic area, sharing the platform's risk profile. The company ceased development of EDP2939 and began exploring strategic alternatives.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e High; the failure suggests the approach for this specific candidate was not unique enough to succeed, evidenced by the primary endpoint miss at 16 weeks.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Not Applicable; development was stopped in \u003cstrong\u003eOctober 2023\u003c\/strong\u003e, and the company subsequently announced plans to dissolve the business in \u003cstrong\u003eNovember 2023\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None; the asset was abandoned before commercialization.\u003c\/p\u003e\n\n\u003cp\u003eThe Phase 2 study (EDP2939-101) involved approximately \u003cstrong\u003e106\u003c\/strong\u003e subjects in Part B, randomized to receive EDP2939 or placebo for moderate plaque psoriasis. The primary endpoint was the proportion achieving a \u003cstrong\u003ePASI-50\u003c\/strong\u003e response at \u003cstrong\u003e16 weeks\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eEDP2939 Group\u003c\/td\u003e\n\u003ctd\u003ePlacebo Group\u003c\/td\u003e\n\u003ctd\u003eTime Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePASI-50 Response Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19.6%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e25%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e16 Weeks\u003c\/strong\u003e (Primary Endpoint)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePASI-50 Response Rate\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e33.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e26.9%\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003eWeek 20\u003c\/strong\u003e (Follow-up)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eThe failure to meet the primary endpoint resulted in Evelo Biosciences' shares dropping approximately \u003cstrong\u003e56%\u003c\/strong\u003e pre-market on October 17, 2023. The stock had previously been priced at \u003cstrong\u003e$16\u003c\/strong\u003e per share upon its \u003cstrong\u003e2018\u003c\/strong\u003e IPO. As of \u003cstrong\u003eSeptember 30\u003c\/strong\u003e, Evelo reported cash and cash equivalents of approximately \u003cstrong\u003e$17.3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eSafety data indicated EDP2939 was well-tolerated, with adverse events comparable to placebo, and no related serious adverse events were reported.\u003c\/p\u003e\n\n\u003cp\u003eKey operational and financial context surrounding the discontinuation:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eDevelopment ceased following the \u003cstrong\u003eOctober 2023\u003c\/strong\u003e readout.\u003c\/li\u003e\n\u003cli\u003eThe company raised \u003cstrong\u003e$25.5 million\u003c\/strong\u003e in a private placement in \u003cstrong\u003eJuly 2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company announced it would cease development of EDP2939 and explore strategic alternatives, including partnering EDP1815 and the SINTAX platform.\u003c\/li\u003e\n\u003cli\u003eThe company's stock fell approximately \u003cstrong\u003e40%\u003c\/strong\u003e in pre-market trade following the announcement.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvelo Biosciences, Inc. (EVLO) - VRIO Analysis: Cash Reserves for Liquidation\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eDirect, immediate value to pay creditors as per the November 2023 dissolution plan is based on the cash on hand as of September 30, 2023, which was approximately \u003cstrong\u003e$17.3 million\u003c\/strong\u003e. This figure is intended to cover claims and obligations before any potential return to stockholders.\u003c\/p\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eLow; cash is a common, though finite, resource in a wind-down scenario.\u003c\/p\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eNot Applicable; this is a balance sheet item, not a dynamic capability.\u003c\/p\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eHigh; an insolvency expert, \u003cstrong\u003eCraig Jalbert\u003c\/strong\u003e, Principal of Verdolino \u0026amp; Lowey, P.C., was appointed to oversee the dissolution process effectively. The board of directors adopted the Plan of Complete Liquidation and Dissolution on Monday, November 20, 2023. The company had previously laid off 48 people in January 2023 and made further cuts in the second quarter.\u003c\/p\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; this resource depletes as creditors are paid.\u003c\/p\u003e\n\u003cp\u003eThe financial position leading up to the dissolution is summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancial Metric\u003c\/td\u003e\n\u003ctd\u003eAmount (Millions USD)\u003c\/td\u003e\n\u003ctd\u003eReporting Period\/Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.3\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$20.63\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Quarter (Q3 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Current Liabilities\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$17.36\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Quarter (Q3 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$8.67\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLatest Quarter (Q3 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccumulated Deficit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$588\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAs of September 30, 2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and Cash Equivalents\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$47.94\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFiscal Year 2022\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific financial and operational details related to the wind-down include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eCraig Jalbert\u003c\/strong\u003e's monthly fee to oversee the dissolution is \u003cstrong\u003e$10,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe departing CEO, Simba Gill, was set to receive \u003cstrong\u003e$3,150 per day\u003c\/strong\u003e for consulting services related to the dissolution.\u003c\/li\u003e\n\u003cli\u003eThe departing CFO, Marella Thorell, was set to receive \u003cstrong\u003e$2,262 per day\u003c\/strong\u003e for consulting services related to the dissolution.\u003c\/li\u003e\n\u003cli\u003eThe company raised \u003cstrong\u003e$25.5 million\u003c\/strong\u003e via a private stock placement in July 2023.\u003c\/li\u003e\n\u003cli\u003eEvelo's initial public offering (IPO) in May 2018 priced shares at \u003cstrong\u003e$16.00\u003c\/strong\u003e apiece.\u003c\/li\u003e\n\u003cli\u003eThe stock's opening price on Wednesday following the dissolution announcement was \u003cstrong\u003e57 cents\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvelo Biosciences, Inc. (EVLO) - VRIO Analysis: Flagship Pioneering Association (Legacy)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eFlagship Pioneering Association (Legacy)\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue: Initial credibility and seed funding from a well-known incubator, which attracted early talent.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe association provided initial resources and credibility, evidenced by:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial capital commitment from Flagship Ventures in 2015 was \u003cstrong\u003e$35 million\u003c\/strong\u003e for Evelo Therapeutics.\u003c\/li\u003e\n\u003cli\u003eFlagship had financed the merged Evelo entity with approximately \u003cstrong\u003e$40 million\u003c\/strong\u003e as of 2016.\u003c\/li\u003e\n\u003cli\u003eFlagship Pioneering's broader track record includes originating and fostering nearly \u003cstrong\u003e100\u003c\/strong\u003e scientific ventures, resulting in over \u003cstrong\u003e$20 billion\u003c\/strong\u003e in aggregate value, \u003cstrong\u003e500+\u003c\/strong\u003e issued patents, and more than \u003cstrong\u003e45\u003c\/strong\u003e clinical trials for novel therapeutic agents.\u003c\/li\u003e\n\u003cli\u003eKey leadership included Dr. Noubar Afeyan, CEO of Flagship Pioneering, serving as Evelo's board chairman.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial milestones directly involving Flagship support:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Event\u003c\/td\u003e\n\u003ctd\u003eDate\u003c\/td\u003e\n\u003ctd\u003eGross Proceeds (USD)\u003c\/td\u003e\n\u003ctd\u003eFlagship Role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial Capital Commitment (Evelo Therapeutics)\u003c\/td\u003e\n\u003ctd\u003e2015\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$35 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInitial Funder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Post-Merger (Evelo\/Epiva)\u003c\/td\u003e\n\u003ctd\u003e2016\u003c\/td\u003e\n\u003ctd\u003eApprox. \u003cstrong\u003e$40 million\u003c\/strong\u003e (to date)\u003c\/td\u003e\n\u003ctd\u003eFinancing Entity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeries B Financing\u003c\/td\u003e\n\u003ctd\u003eJuly 2017\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$50 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFounding and Principal Investor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistered Direct Offering\u003c\/td\u003e\n\u003ctd\u003eMay 2022\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$79.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eOffering Lead Investor\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eRarity: Association with Flagship Pioneering is rare for a startup, but its protective value has expired.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe initial creation within Flagship VentureLabs is a rare origin point for a life sciences company. However, the protective value diminished as evidenced by the \u003cstrong\u003e$79.2 million\u003c\/strong\u003e registered direct offering in May 2022, which was led by Flagship but included other new and existing investors.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability: The association is historical and cannot be replicated post-dissolution.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eEvelo Biosciences was conceived and created within Flagship VentureLabs in \u003cstrong\u003e2015\u003c\/strong\u003e. The company's subsequent dissolution in \u003cstrong\u003eNovember 2023\u003c\/strong\u003e renders the historical association non-replicable for future operational benefit.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization: The association did not prevent the ultimate failure to secure follow-on funding.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe company ultimately determined dissolution was the only viable option after failing to secure funding. Key financial indicators preceding dissolution:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eWork on drug candidate EDP1867 stopped in April \u003cstrong\u003e2022\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eLead candidate EDP1815 failed a Phase 2 clinical trial in February \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe last asset, EDP2939, failed in October \u003cstrong\u003e2023\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eAs of September 30, 2023, cash on hand was approximately \u003cstrong\u003e$17.3 million\u003c\/strong\u003e, against debt of \u003cstrong\u003e$43.9 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's shares lost almost all their value since its IPO in \u003cstrong\u003e2018\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage: None; the association is a historical fact, not a current operational asset.\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe company's Nasdaq trading ticker was EVLO. The company's IPO priced shares at \u003cstrong\u003e$16\u003c\/strong\u003e apiece in \u003cstrong\u003e2018\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvelo Biosciences, Inc. (EVLO) - VRIO Analysis: Clinical Trial Data (Negative \u0026amp; Positive Signals)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Data packages, even from failures, hold residual value for potential acquirers of the IP or platform.\u003c\/p\u003e\n\u003cp\u003eThe company was exploring strategic alternatives, including seeking partnership opportunities for its proprietary SINTAX platform following the EDP2939 Phase 2 results. As of year-end 2022, Evelo reported a cash position of \u003cstrong\u003e$47.9 million\u003c\/strong\u003e, following a net loss of \u003cstrong\u003e$114.5 million\u003c\/strong\u003e in 2022. As of June 2023-end, cash and cash equivalents stood at \u003cstrong\u003e$7.6 million\u003c\/strong\u003e against a debt balance of approximately \u003cstrong\u003e$43.9 million\u003c\/strong\u003e, which followed a \u003cstrong\u003e$25.5 Million\u003c\/strong\u003e Private Placement closure in July 2023. The company had previously secured a \u003cstrong\u003e$45 million\u003c\/strong\u003e loan agreement in December 2022 to refinance existing debt.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Moderate; the specific human data on gut-immune modulation is unique, despite the negative outcomes.\u003c\/p\u003e\n\u003cp\u003eThe platform generated data on orally delivered medicines acting on the SINTAX, the small intestinal axis. The first EV candidate, EDP2939, commenced dosing in a Phase 2 psoriasis trial, marking the first oral delivery of a bacterial EV medicine to humans with no reported safety concerns.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the data is documented and transferable, though its interpretation is key.\u003c\/p\u003e\n\u003cp\u003eThe documented clinical outcomes, both positive and negative, are transferable assets.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate; the data exists, but the team that generated and understood it has largely departed.\u003c\/p\u003e\n\u003cp\u003eThe company announced a process to explore strategic alternatives after the October 2023 results. The total number of Shares Outstanding (Ticker) was reported as \u003cstrong\u003e18.98M\u003c\/strong\u003e. The stock plunged \u003cstrong\u003e58.8%\u003c\/strong\u003e following the EDP2939 top-line results, and year-to-date shares had plunged \u003cstrong\u003e96.3%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; value is only present during the asset sale phase.\u003c\/p\u003e\n\u003cp\u003eThe residual value is tied to the potential sale or licensing of the SINTAX platform or specific pipeline candidates.\u003c\/p\u003e\n\u003cp\u003eClinical Trial Data Summary:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial\/Candidate\u003c\/td\u003e\n\u003ctd\u003eIndication\u003c\/td\u003e\n\u003ctd\u003eEndpoint\/Signal\u003c\/td\u003e\n\u003ctd\u003eResult Metric\u003c\/td\u003e\n\u003ctd\u003eValue vs. Placebo\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDP2939\u003c\/td\u003e\n\u003ctd\u003eModerate Psoriasis (Phase 2)\u003c\/td\u003e\n\u003ctd\u003ePrimary Endpoint (Week 16) - Negative\u003c\/td\u003e\n\u003ctd\u003ePASI-50 Response Rate\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e19.6%\u003c\/strong\u003e (EDP2939) vs \u003cstrong\u003e25%\u003c\/strong\u003e (Placebo)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDP2939\u003c\/td\u003e\n\u003ctd\u003eModerate Psoriasis (Phase 2)\u003c\/td\u003e\n\u003ctd\u003eFollow-up (Week 20) - Positive Signal\u003c\/td\u003e\n\u003ctd\u003ePASI-50 Response Rate\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e33.9%\u003c\/strong\u003e (EDP2939) vs \u003cstrong\u003e26.9%\u003c\/strong\u003e (Placebo)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDP1815\u003c\/td\u003e\n\u003ctd\u003eModerate Psoriasis (Phase 2)\u003c\/td\u003e\n\u003ctd\u003ePASI-50 Response Rate (Week 16) - Positive Signal\u003c\/td\u003e\n\u003ctd\u003ePASI-50 Response Rate\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e25%\u003c\/strong\u003e to \u003cstrong\u003e32%\u003c\/strong\u003e vs \u003cstrong\u003e12%\u003c\/strong\u003e (Placebo) across cohorts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEDP1815\u003c\/td\u003e\n\u003ctd\u003eAtopic Dermatitis (Phase 2, Cohort 4)\u003c\/td\u003e\n\u003ctd\u003ePrimary Endpoint - Negative\u003c\/td\u003e\n\u003ctd\u003eEASI-50 Response Rate (Week 16)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e37.9%\u003c\/strong\u003e vs \u003cstrong\u003e44.7%\u003c\/strong\u003e (Placebo)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional Data Points:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePhase 1b trial of EDP1815 showed treatment resulted in clinically meaningful improvement in Dermatology Life Quality Index ('DLQI') and Patient-Oriented Eczema Measure (POEM) at day 56.\u003c\/li\u003e\n\u003cli\u003eAll five measures of itch within the Pruritus-Numerical Rating Scale showed greater improvements in the treated group at day 56 compared with placebo in the Phase 1b trial.\u003c\/li\u003e\n\u003cli\u003eAs of March 5, 2021, there were \u003cstrong\u003e53,334,947\u003c\/strong\u003e shares of the registrant's common stock outstanding.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvelo Biosciences, Inc. (EVLO) - VRIO Analysis: Experienced Scientific Team (Legacy Knowledge)\n\u003c\/h2\u003e\n\n\u003cp\u003eThe analysis of the experienced scientific team's legacy knowledge is framed against the backdrop of the company's November 20, 2023, announcement of planned dissolution.\u003c\/p\u003e\n\n\u003ch\u003eValue\u003c\/h\u003e\n\u003cp\u003eDeep, specialized knowledge in the gut-immune axis, valuable to any entity acquiring the remaining IP. Research and Development Expenses were $60.3 million in 2022. The platform focuses on orally delivered investigational medicines acting on SINTAX™, the small intestinal axis.\u003c\/p\u003e\n\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003cp\u003eModerate; expertise in this niche area is not common, though key leaders have left. The company laid off 48 people in January 2023.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eBoard of Directors resigned on November 20, 2023: Juan Andres, Balkrishan (Simba) Gill, Ph.D., Jose-Carlos Gutiérrez-Ramos, Ph.D., Jeffrey R. Moore, Alexander C. Reynolds, Robert L. Rosiello, and Tonya Williams.\u003c\/li\u003e\n\u003cli\u003eCEO Balkrishan (Simba) Gill, Ph.D., and CFO Marella Thorell separated from the company.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003cp\u003eModerate; knowledge transfer is difficult, but the core concepts are published. The company held 37 issued patents protecting core technology as of a prior analysis.\u003c\/p\u003e\n\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003cp\u003eLow; the core team and board resigned upon announcing dissolution plans. Cash and cash equivalents on hand were approximately $17.3 million as of September 30, 2023. The company raised $25.5 million via a private stock placement in July 2023.\u003c\/p\u003e\n\n\u003cp\u003eThe financial impact and transition arrangements for key scientific and executive personnel are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003ePersonnel Role\u003c\/th\u003e\n\u003cth\u003eName\u003c\/th\u003e\n\u003cth\u003ePre-Separation Annual Compensation (2022)\u003c\/th\u003e\n\u003cth\u003ePost-Employment Consulting Rate\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Executive Officer\u003c\/td\u003e\n\u003ctd\u003eBalkrishan (Simba) Gill, Ph.D.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1,721,635\u003c\/strong\u003e (Total)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$3,150\u003c\/strong\u003e per diem\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChief Financial Officer\u003c\/td\u003e\n\u003ctd\u003eMarella Thorell\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1,029,097\u003c\/strong\u003e (Total)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$2,262\u003c\/strong\u003e per diem\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePresident of R\u0026amp;D and CSO (2021)\u003c\/td\u003e\n\u003ctd\u003eMark W. Bodmer, Ph.D.\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e£355,555.00\u003c\/strong\u003e (Base Salary 2021)\u003c\/td\u003e\n\u003ctd\u003eN\/A (Employment Agreement dated Dec 31, 2021)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInsolvency Expert\/New Officer\u003c\/td\u003e\n\u003ctd\u003eCraig R. Jalbert\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$10,000\u003c\/strong\u003e per month (until dissolution filing)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003cp\u003eTemporary; any remaining value is tied to consultants like the former CEO and CFO. The insolvency expert, Mr. Jalbert, is contracted for $50,000 per year for three years following the Certificate of Dissolution filing.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eEvelo Biosciences, Inc. (EVLO) - VRIO Analysis: Oral Drug Delivery Expertise\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOral Drug Delivery Expertise\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eValue: Demonstrated ability to formulate microbial strains into orally administered capsules (e.g., EDP1815 formulation selection). The enteric capsule formulation of EDP1815 was selected for the Phase 2 trial in mild to moderate psoriasis based on formulation trial results. Clinical data showed a pooled PASI-50 response rate of 29% for EDP1815 across three cohorts versus 12% for placebo in the psoriasis Phase 2 study, with a statistically significant p-value of 0.027 for the pooled analysis. In contrast, an Atopic Dermatitis Phase 2 trial showed EASI-50 responses of 41%, 38%, and 32% for EDP1815 cohorts against a placebo response of 56%.\u003c\/p\u003e\n\u003cp\u003eRarity: Moderate; formulation science for biologics is specialized, but not unique in the broader pharma space.\u003c\/p\u003e\n\u003cp\u003eImitability: Moderate; competitors can hire experts or license formulation know-how.\u003c\/p\u003e\n\u003cp\u003eOrganization: Low; the team responsible for this execution is no longer in place to drive new development. The company announced workforce reductions in February 2023 to extend cash runway. As of the latest quarter, total assets were reported at $20.63 million against total liabilities of $39.76 million. The Q3 2023 net income was $-12.36M.\u003c\/p\u003e\n\u003cp\u003eCompetitive Advantage: Temporary; the know-how is embedded in documentation, not an active capability.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eVRIO Attribute\u003c\/th\u003e\n\u003cth\u003eAssessment\u003c\/th\u003e\n\u003cth\u003eSupporting Data\/Evidence\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eYes\u003c\/td\u003e\n\u003ctd\u003eEnteric capsule formulation selected for EDP1815. Psoriasis PASI-50 response: 29% vs. 12% placebo.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRarity\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eSpecialized formulation science for orally administered microbial strains.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInimitability\u003c\/td\u003e\n\u003ctd\u003eModerate\u003c\/td\u003e\n\u003ctd\u003eKnow-how is potentially codifiable and transferable through hiring\/licensing.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrganization\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003ctd\u003eWorkforce reduction announced Feb 2023. Latest quarter Total Assets: $20.63M; Total Liabilities: $39.76M.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n\u003ctd\u003eTemporary\u003c\/td\u003e\n\u003ctd\u003eKnow-how is documented but active capability\/team structure is diminished.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe oral formulation expertise is tied to specific product development milestones:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEDP1815 is a non-live pharmaceutical preparation of Prevotella histicola selected for systemic effects after oral administration with gut-restricted distribution.\u003c\/li\u003e\n\u003cli\u003eThe Phase 2 psoriasis trial evaluated three doses of the enteric capsule formulation versus placebo in 249 patients over a 16-week treatment period.\u003c\/li\u003e\n\u003cli\u003eThe company's shares have lost nearly all value since debuting at $16 apiece in 2018.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516160991381,"sku":"evlo-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/evlo-vrio-analysis.png?v=1740171767","url":"https:\/\/dcf-model.com\/pt\/products\/evlo-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}